A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.
Also called NCT02906917
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 532 participants
- Sponsor
- Registry
-
NCT02906917 -
2015-004768-12
-
- Other papers using this trial's data
- Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Czechia, India, Russia, Serbia, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02906917. Randomized; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2017-08-31 (actual). Results posted on 2018-09-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin degludec/insulin aspart
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02906917- Content hash
9047bfbaaf06f3c48c5d71ba0f09e2597e9f0039b4eb2caf4f921e3c1b7fe015